210 related articles for article (PubMed ID: 34530482)
1. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
Agnelli G; Muñoz A; Franco L; Mahé I; Brenner B; Connors JM; Gussoni G; Hamulyak EN; Lambert C; Suero MR; Bauersachs R; Torbicki A; Becattini C
Thromb Haemost; 2022 May; 122(5):796-807. PubMed ID: 34530482
[TBL] [Abstract][Full Text] [Related]
2. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
3. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
[TBL] [Abstract][Full Text] [Related]
4. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.
Becattini C; Bauersachs R; Maraziti G; Bertoletti L; Cohen A; Connors JM; Manfellotto D; Sanchez A; Brenner B; Agnelli G
Haematologica; 2022 Jul; 107(7):1567-1576. PubMed ID: 34382385
[TBL] [Abstract][Full Text] [Related]
5. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
[TBL] [Abstract][Full Text] [Related]
6. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
Ageno W; Vedovati MC; Cohen A; Huisman M; Bauersachs R; Gussoni G; Becattini C; Agnelli G
Thromb Haemost; 2021 May; 121(5):616-624. PubMed ID: 33202447
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
Giustozzi M; Connors JM; Ruperez Blanco AB; Szmit S; Falvo N; Cohen AT; Huisman M; Bauersachs R; Dentali F; Becattini C; Agnelli G
J Thromb Haemost; 2021 Nov; 19(11):2751-2759. PubMed ID: 34260816
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
[No Abstract] [Full Text] [Related]
9. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
[TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
11. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
Verso M; Agnelli G; Munoz A; Connors JM; Sanchez O; Huisman M; Brenner B; Gussoni G; Cohen AT; Becattini C
Eur J Cancer; 2022 Apr; 165():136-145. PubMed ID: 35235870
[TBL] [Abstract][Full Text] [Related]
12. In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding.
Riaz IB; Marshall AL; Badgett RG
Ann Intern Med; 2020 Aug; 173(4):JC21. PubMed ID: 32805168
[TBL] [Abstract][Full Text] [Related]
13. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
Francis CW; Kessler CM; Goldhaber SZ; Kovacs MJ; Monreal M; Huisman MV; Bergqvist D; Turpie AG; Ortel TL; Spyropoulos AC; Pabinger I; Kakkar AK
J Thromb Haemost; 2015 Jun; 13(6):1028-35. PubMed ID: 25827941
[TBL] [Abstract][Full Text] [Related]
14. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
Agnelli G; Becattini C; Bauersachs R; Brenner B; Campanini M; Cohen A; Connors JM; Fontanella A; Gussoni G; Huisman MV; Lambert C; Meyer G; Muñoz A; Abreu de Sousa J; Torbicki A; Verso M; Vescovo G;
Thromb Haemost; 2018 Sep; 118(9):1668-1678. PubMed ID: 30103252
[TBL] [Abstract][Full Text] [Related]
15. Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.
Cohen AT; Creeper KJ; Alikhan R; Er C; Connors JM; Huisman MV; Munoz A; Vescovo G; Bauersachs R; Ageno W; Agnelli G; Becattini C
Thromb Haemost; 2024 Jan; ():. PubMed ID: 38196077
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.
Mulder FI; van Es N; Kraaijpoel N; Di Nisio M; Carrier M; Duggal A; Gaddh M; Garcia D; Grosso MA; Kakkar AK; Mercuri MF; Middeldorp S; Royle G; Segers A; Shivakumar S; Verhamme P; Wang T; Weitz JI; Zhang G; Büller HR; Raskob G
Thromb Res; 2020 Jan; 185():13-19. PubMed ID: 31733403
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of cancer-associated venous thromboembolism].
Di Nisio M
G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
[TBL] [Abstract][Full Text] [Related]
19. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
[TBL] [Abstract][Full Text] [Related]
20. [Modern anticoagulation with factor Xa inhibitors in oncology: is the gastrointestinal bleeding rate (also) decisive?].
Raithel M; Haibach M; Kremenevski I; Arnold E; Ringwald J
Z Gastroenterol; 2023 Apr; 61(4):411-419. PubMed ID: 35878607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
